PARATHYROID HORMONE (PTH) ANALOGS Market to Reach $1.85 Billion by 2025

ASHBURNHAM, Mass. - Aug. 4, 2025 - PRLog -- PARATHYROID HORMONE (PTH) ANALOGS Market to Reach $1.85 Billion by 2025, Driven by Growing Demand in Osteoporosis Treatment

Market to Expand at 17% CAGR Through 2032 Amidst Rising Geriatric Population and Advancements in Hormonal Therapies

The global Parathyroid Hormone (PTH) Analogs Market is projected to reach $1.85 billion by 2025, growing at a compound annual growth rate (CAGR) of 17% from 2025 to 2032. This robust growth is fueled by increasing prevalence of osteoporosis, hypoparathyroidism, and other calcium metabolism disorders. Technological advancements in peptide-based therapies and rising awareness of early hormonal disorder management are further accelerating demand. North America holds the dominant market share, followed by Europe and Asia-Pacific, where healthcare infrastructure investments are steadily increasing.

Key application areas driving the market include osteoporosis treatment in postmenopausal women, a segment that continues to see high clinical demand due to aging populations in developed regions. Another significant segment is hypoparathyroidism therapy, with recombinant PTH analogs becoming a preferred long-term treatment. Additionally, off-label uses in calcium homeostasis disorders are contributing to broader market adoption, especially in research-focused medical centers.

Price trends for PTH analogs showed a notable uptick between 2024 and 2025, particularly in the United States and Germany, where the average price per dose increased by 6–8% due to higher raw material costs and stricter regulatory compliance. In contrast, India saw more stable pricing owing to expanded domestic manufacturing and generic competition. Overall, innovation-driven production and growing demand for personalized endocrine therapies are expected to keep prices moderately elevated through 2026.

Leading companies in the PTH analogs market include Amgen Inc. and Eli Lilly and Company in North America, which dominate in innovation and global market penetration. Kyowa Kirin Co., Ltd. represents a strong player in Asia, focusing on specialty hormone therapies. Ipsen in Europe continues to expand its portfolio through R&D and strategic collaborations. These companies are investing in next-generation analog formulations and expanding distribution networks in emerging markets.

With favorable demographic trends, growing endocrine research, and a strong pipeline of advanced biologics, the PTH analogs market is poised for sustained growth well beyond 2025.

Request for customization https://datavagyanik.com/reports/parathyroid-hormone-pth-analogs-market/